LON:OXB - Oxford BioMedica Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 888.40 -17.60 (-1.94 %)
(As of 07/16/2018 03:06 AM ET)
Previous CloseGBX 906
Today's RangeGBX 874.80 - GBX 906.40
52-Week RangeGBX 4.44 - GBX 13.19
Volume129,896 shs
Average Volume6.89 million shs
Market Capitalization£388.67 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oxford BioMedica logoOxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, and Immune Design. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Receive OXB News and Ratings via Email

Sign-up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:OXB
CUSIPN/A
Phone+44-1865-783000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-21.31%
Return on Equity-56.98%
Return on Assets-11.53%

Miscellaneous

EmployeesN/A
Outstanding Shares3,110,000,000
Market Cap£388.67

The Truth About Cryptocurrencies

Oxford BioMedica (LON:OXB) Frequently Asked Questions

What is Oxford BioMedica's stock symbol?

Oxford BioMedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

What price target have analysts set for OXB?

3 Wall Street analysts have issued 1 year price objectives for Oxford BioMedica's stock. Their predictions range from GBX 10.20 to GBX 16. On average, they expect Oxford BioMedica's share price to reach GBX 13.07 in the next year. This suggests that the stock has a possible downside of 98.5%. View Analyst Ratings for Oxford BioMedica.

What is the consensus analysts' recommendation for Oxford BioMedica?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford BioMedica in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Oxford BioMedica's key competitors?

Who are Oxford BioMedica's key executives?

Oxford BioMedica's management team includes the folowing people:
  • Mr. John Dawson, Chief Exec. Officer and Exec. Director (Age 58)
  • Mr. Peter Nolan, Chief Bus. Officer & Exec. Director (Age 65)
  • Mr. Timothy William Watts, Exec. Officer (Age 60)
  • Mr. Stuart Paynter, CFO & Director
  • Mr. Nick Page, Chief Operations Officer

Has Oxford BioMedica been receiving favorable news coverage?

Media headlines about OXB stock have trended positive this week, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oxford BioMedica earned a news sentiment score of 0.36 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 45.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Oxford BioMedica?

Shares of OXB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Oxford BioMedica's stock price today?

One share of OXB stock can currently be purchased for approximately GBX 888.40.

How big of a company is Oxford BioMedica?

Oxford BioMedica has a market capitalization of £388.67 million.

How can I contact Oxford BioMedica?

Oxford BioMedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-783000.


MarketBeat Community Rating for Oxford BioMedica (LON OXB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica and other stocks. Vote "Outperform" if you believe OXB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.